15 Feb 2024
Breast Cancer Index® and Forecasting Risk of Recurrence
If you were recently diagnosed with early-stage hormone receptor-positive (hormone-positive or HR+) breast cancer, understanding the Breast Cancer Index® test can help you and your cancer care team determine if extending hormonal therapy for five additional years (a sum of ten years) would be beneficial. This unique, proprietary genomic test analyzes the activity of eleven genes in your tumor tissue, helping to identify your risk of breast cancer recurrence. With this life-changing knowledge in the palm of your hand, you and your healthcare team can make the right treatment decision.
